- Acquired by Undisclosed, Jun 2026
- Raised $16M funding round led by RunYoung Technology Transfer Center, Apr 2021
- Raised $14M funding round, Jan 2009
About
VESSL Therapeutics develops cell-based therapies for patients who suffer from cardiovascular and other vascular-related conditions and cannot be treated adequately with existing therapeutic modalities. Its core technology is based on an integrative approach for the treatment of cardiovascular disease. VESSLs two leading products, MultiGeneAngio and MultiGeneGraft, have been approved by the FDA for clinical studies, and two phase 1/2 clinical trials with MultiGeneAngio have been completed. MultiGeneAngio is a combination of two cell types and two genes, and MultiGeneGraft is the combination of cells, genes, and a synthetic graft. These two technologies are used in therapies for patients with peripheral artery disease and coronary artery disease, and for patients with renal disease requiring hemodialysis. The companys products are based on the patients own cells, isolated from a short vein segment taken from the patients arm under local anesthesia. The isolated cells are activated by the insertion of specific genes and then reintroduced to the patient. The FDA has granted an Investigational New Drug (IND) authorization for MultiGeneGraft.
Funding history · 2 rounds · $30.0M total
Q&A
- What is VESSL Therapeutics' primary focus?
- VESSL Therapeutics focuses on developing cell-based therapies for patients suffering from cardiovascular and other vascular-related conditions that are not adequately treated by existing methods.
- When was VESSL Therapeutics founded?
- VESSL Therapeutics was founded in October 2000.
- What is the current status of VESSL Therapeutics?
- VESSL Therapeutics is currently non-active, having ceased operations in June 2026.
- What are VESSL Therapeutics' two leading products?
- VESSL Therapeutics' two leading products are MultiGeneAngio and MultiGeneGraft, both approved by the FDA for clinical studies.
- Which investors participated in VESSL Therapeutics' April 2021 funding round?
- In April 2021, VESSL Therapeutics raised $16,000,000 from RunYoung Technology Transfer Center.
- Which investors participated in VESSL Therapeutics' January 2009 funding round?
- In January 2009, VESSL Therapeutics raised $14,000,000 from Aviv Venture Capital and Teva Pharmaceuticals.
- What is the total amount of funding VESSL Therapeutics has raised to date?
- VESSL Therapeutics has raised a total of $30,000,000.
- How many employees does VESSL Therapeutics have?
- VESSL Therapeutics has 1-10 employees.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/1175843 |
Identifiers & details
| Former names | MGVS, MultiGene Vascular Systems |
|---|---|
| Founded | 2000-10 |
| Employees (exact) | 2 |
Acquisitions & public offerings
Acquired by Undisclosed 2026-06